

Datasheet: HCA235G BATCH NUMBER 1709

Description:	HUMAN ANTI OMALIZUMAB
Specificity:	OMALIZUMAB
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD20669_hlgG1
lsotype:	lgG1
Quantity:	1 mg

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .					
		Yes	No	Not Determined	Suggested Dilution	
	ELISA Where this product has ı	• not boon tr	ested for	use in a particular tech	nique this does not	
	necessarily exclude its u a guide only. It is recommon system using appropriate	ise in such mended th	procedu at the us	res. Suggested working er titrates the product fo	g dilutions are given as	
Product Form	Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.					
Preparation	Purified IgG prepared by affinity chromatography on Protein A					
Buffer Solution	Phosphate buffered saline					
Preservative Stabilisers	0.01% Thiomersal					
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml					
Immunogen	Omalizumab					
Specificity	Human Anti-Omalizum anti-idiotypic antibody th drug/immunoglobulin co	at binds sp	pecifically	v to omalizumab but no	t to free IgE or the	

omalizumab and biosimilar products in bioanalytical assays.

Clone AbD20669_hlgG1 can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, HRP-conjugated and in full immunoglobulin (Ig) format, is recommended as the detection antibody, paired with the antibody in monovalent Fab format, clone AbD20669 (HCA236), as the capture antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

Omalizumab (brand name Xolair) is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody used in the treatment of patients with moderate or severe asthma who have demonstrated a positive allergy skin test and whose symptoms are not controlled by inhaled corticosteroids.

Allergic asthma is mediated by IgE released by B cells in response to allergen. Circulating IgE binds to the high-affinity IgE Fc receptor (Fc ϵ RI) expressed on basophils and mast cells, triggering the release of histamine, leukotrienes and other mediators associated with the pathophysiology of asthma. Omalizumab is directed against the Fc region of human immunoglobulin E (IgE). By binding to circulating IgE at the site of Fc ϵ RI binding, this therapeutic antibody prevents the interaction of IgE with its receptor thus limiting mediator release. Treatment with omalizumab has also been demonstrated to reduce the expression of Fc ϵ RI on mast cells and basophils, providing additional clinical benefit.

View a summary of all Anti-Omalizumab Antibodies

Affinity	The monovalent intrinsic affinity of this antibody was measured as $K_D = 1.1$ nM by real time, label free molecular interaction analysis on immobilized omalizumab.
ELISA	This product may be used as bridging reagent in ADA assay development or, following HRP-conjugation, as a detection reagent in PK assay development together with <u>HCA236</u> as the capture reagent. Protocol: <u>PK bridging ELISA to measure free drug</u> Protocol: <u>ADA bridging ELISA</u>
References	1. Kashiwagi, N. <i>et al</i> . (2017) Method for measuring anti-drug antibody <u>US Patent</u> application US20170315118A1
Storage	Store at +4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	12 months from date of despatch
Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.

Xolair is a registered trademark of Novartis.

Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA235G 10094		
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.		
Regulatory	For research purposes only		
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u>		

Related Products

Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A) LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P) RECOMBINANT HUMAN IgE LAMBDA (HCA171) RECOMBINANT HUMAN IgE KAPPA (HCA190) HUMAN ANTI OMALIZUMAB (HCA236) HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX) (HCA237) HUMAN ANTI OMALIZUMAB (DRUG/TARGET COMPLEX) (HCA238)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50
	Email: antibody_sales_us@bio-ra	ad.com	Email: antibody_sales_uk@bio-	rad.com	Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M371660:200612'

Printed on 16 May 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint